BM-2216

N/A

Report date: 2025/10/17 20:01:39
NME

Base Information

Drug NameBM-2216
Drug Alias NameBM2216缓释片ALK-M001缓释片BM2216BM-2216BM2216-ER +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsDiabetic peripheral neuropathic painDiabetes MellitusNeuralgia +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesZhejiang Anglikang Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Baimai Bio Tech Co LtdZhejiang Anglikang Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic peripheral neuropathic painDiabetes MellitusNeuralgia +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A